Spero Therapeutics, Inc. (SPRO)
| Market Cap | 391.52M |
| Revenue (ttm) | 14.93M |
| Net Income (ttm) | -74.45M |
| Shares Out | 29.41M |
| EPS (ttm) | -3.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $12.39 |
| Previous Close | $13.42 |
| Change ($) | -1.03 |
| Change (%) | -7.68% |
| Day's Open | 13.42 |
| Day's Range | 12.36 - 13.42 |
| Day's Volume | 154,149 |
| 52-Week Range | 8.50 - 23.64 |
CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...
Tebipenem HBr advancing towards NDA submission in the second half of 2021
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is run...
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...
15 data presentations cover each of Spero's three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Spero's three ...
Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...
The pricing of a stock offering is causing the drugmaker's shares to fall.
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and...
The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q2 2020 Results - Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 27.35% and -41.46%, respectively, for the quarter ended June 2020.
Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. (SPRO).
Spero Therapeutics, Inc. (SPRO) CEO Dr.
Spero Therapeutics Inc (SPRO) delivered earnings and revenue surprises of 9.63% and -49.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020
ADAPT-PO topline results expected in the third quarter of 2020 ADAPT-PO topline results expected in the third quarter of 2020
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...
Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott Jackson Spero brings significant commercial...
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019.
CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi...
$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 $30 Million fully backstopped rights offering will be available to all stockholders of ...
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment ... [Read more...]
| Industry Biotechnology | IPO Date Nov 2, 2017 |
| CEO Ankit Mahadevia | Employees 89 |
| Stock Exchange NASDAQ | Ticker Symbol SPRO |
Financial Performance
In 2020, SPRO's revenue was $9.33 million, a decrease of -48.59% compared to the previous year's $18.15 million. Losses were -$78.28 million, 28.5% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 166.34% from the latest price.